FDA authorizes first direct-to-consumer genetic test panel for predisposition to Alzheimer’s disease and other serious disorders

The FDA has announced its decision to grant a de novo application submitted by 23andMe for the company’s direct-to-consumer (DTC) Personal Genome Service Genetic Health Risk (“GHR") tests. The GHR test panel currently includes genetic variants…By: DLA Piper http://www.jdsupra.com/legalnews/fda-authorizes-first-direct-to-consumer-40610/